CAMLIN are pleased to announce that our ARC-Intellicare system has been approved to move into clinical validation trials. The system is designed to be used at home to allow patients to improve their physical rehabilitation and speed of recovery within the first six months of suffering a stroke. It offers both patient and therapist the ability to accurately monitor exercise and activity and permits the therapist to customise the rehabilitation to individual patient circumstances.

The system utilises several accelerometer sensors (worn on the limbs) to capture and monitor exercises performed by the patient and their daily activity during the crucial first weeks and months of rehabilitation. The trial will assess the progress of some 300 patients, in both Italy and Northern Ireland, and is scheduled to run for 18 months.

Our expertise in Artificial Intelligence and Machine Learning makes ARC unique by:

  • Understanding and interpretation of the patient exercises and contextual information on their everyday activities;
  • Enabling patient specific exercise programmes to be developed;
  • Trending the patient’s progress during the rehabilitation period;
  • Providing qualitative and quantitative feed-back to the therapist on patient progress.

CAMLIN CEO, John Cunningham said:

“It is with tremendous excitement that we take our ARC-Intellicare system to clinical trials. Stroke is an issue that directly or indirectly affects the lives of many people and our ARC system is a huge step forward, empowering patients and their carers to take control of their rehabilitation and recovery.”